Results 161 to 170 of about 28,373,227 (361)

The contingent roles of R&D–sales versus R&D–marketing cooperation in new-product development of business-to-business firms

, 2016
Christian Homburg, Sascha Alavi, Thomas Rajab, Jan Wieseke   +3 more
openalex   +2 more sources

The mechanics of shuffle products and their siblings

, 2015
We carry on the investigation initiated in [15] : we describe new shuffle products coming from some special functions and group them, along with other products encountered in the literature, in a class of products, which we name $\varphi$-shuffle ...
Duchamp, Gérard H. E., Enjalbert, Jean-Yves, Hoang, Vincel, Tollu, Christophe   +3 more
core   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

A New Partial Product Reduction Algorithm using Modified Counter and Optimized Hybrid Network [PDF]

, 2015
Pouya Asadi
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Critical success factors of new product development in technology based firms: A case study

, 2012
Kamariah Ismail
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

New Biotechnology for the Production of Phytocompounds from Secondary Products of Grain Processing

, 2019
Анна Битюкова, Anna Bityukova, Александра Амелькина, Alexandra Amelkina, Александр Евтеев, Alexander V. Evteev, А. В. Банникова, А. В. Банникова   +7 more
openalex   +1 more source

Structural Constraints, Strategic Interactions and Innovative Processes: Measuring Network Effects in New Product Development Projects [PDF]

, 2000
Maurizio Sobrero
openalex   +1 more source